• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Comparable immune escape capacity for NB.1 with that of JN.1 variant and survey of infection with severe acute respiratory syndrome

tetano

Editor, Senior Moderator
Front Immunol


. 2026 Jan 27:17:1766267.
doi: 10.3389/fimmu.2026.1766267. eCollection 2026.
Comparable immune escape capacity for NB.1 with that of JN.1 variant and survey of infection with severe acute respiratory syndrome coronavirus 2 variants among Chinese Felis silvestris catus

Youhua Yuan[SUP] 1 [/SUP], Yiman Geng[SUP] #[/SUP][SUP] 2 [/SUP], Qiyuan Zhu[SUP] #[/SUP][SUP] 3 [/SUP], Bingfu Sun[SUP] #[/SUP][SUP] 4 [/SUP], Junhong Xu[SUP] 5 [/SUP], Xiaohuan Mao[SUP] 1 [/SUP], Xiaohuan Zhang[SUP] 1 [/SUP], Wenqian Tian[SUP] 1 [/SUP], Jing Zhao[SUP] 2 [/SUP], Peiming Zheng[SUP] 4 [/SUP], Lan Gao[SUP] 4 [/SUP]


Affiliations
Abstract

Background: Neutralising antibodies and infection with the newest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant NB.1 in Chinese Felis silvestris catus remains unclear. This study compared the capability of neutralising antibodies in serum against the NB.1 variant prevalent in 2025 with that of the JN.1 variant circulating in 2024 among ill Chinese Felis silvestris catus, and determined whether they could be infected with SARS-CoV-2 variants.
Methods: A total of 392 serum samples from ill cats were subjected to enzyme-linked immunosorbent assay (ELISA) to detect the concentration of total antibodies against the receptor-binding domain of SARS-CoV-2; 40 serum samples screened positive by ELISA were subjected to pseudovirus neutralisation test to detect the titres of neutralising antibodies against the JN.1 and NB.1 variants, and 132 throat swab samples from ill cats were screened using specific reverse transcription polymerase chain reaction.
Results: The geometric mean neutralising titres against the total, NB.1, and JN.1 Omicron variants were 9.51 (95% confidence interval: 7.34-12.3), 24.26 (18.84-31.23), and 48.79 (36.51-65.21) among 40 serum samples from ill cats, respectively. Therefore, neutralisation assays against JN.1 and NB.1 indicated 5.1- and 2.6-fold reductions in neutralising antibody titres, respectively, compared with the total antibody. Additionally, NB.1 showed a 2.91-fold reduction in neutralising antibody titres compared with JN.1. None of the throat swabs from the 132 ill cats were found to be infected with SARS-CoV-2 variants.
Conclusions: NB.1 showed increased immune escape capacity in serum compared with JN.1 among Chinese Felis silvestris catus, suggesting that researchers should include the NB.1 antigen in COVID-19 vaccine candidates.

Keywords: Felis silvestris catus; JN.1; NB.1; enzyme-linked immunosorbent assay; immune escape; pseudovirus neutralisation test.

 
Back
Top Bottom